Characterization of a Hypoallergenic Recombinant Bet v 1 Variant as a Candidate for Allergen-Specific Immunotherapy
Authors:
- H. KahlertHKH. Kahlert
- R. SuckRSR. Suck
- B. WeberBWB. Weber
- A. NandyANA. Nandy
- M. WaldMWM. Wald
- W. KellerWKW. Keller
- O. CromwellOCO. Cromwell
- H. FiebigHFH. Fiebig
- 2 October 2007
- journal article
- research article
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 145 (3) , 193-206
Abstract
Background: Recombinant allergens and especially their hypoallergenic variants are promising candidates for a more effective and safer specific immunotherapy. Methods: Physicochemical and immunological characteristics of a folding variant of recombinant Bet v 1 (rBet v 1-FV) were investigated in comparison to natural Bet v 1 (nBet v 1) and the correctly folded recombinant Bet v 1 (rBet v 1-WT) by SDS-PAGE, size exclusion chromatography, multi-angle light scattering, circular dichroism, immunoblotting and enzyme allergosorbent test inhibition assay for detection of IgE reactivity and ELISA with Bet v 1-specific monoclonal antibodies. The functional IgE reactivity of the different Bet v 1 proteins was investigated using basophil activation in terms of CD203c expression and histamine release. T cell reactivity was investigated using T cell lines raised from birch pollen-allergic subjects against nBet v 1. Immunogenicity was investigated in mice. Results: Physicochemical characterization revealed purity, homogeneity and monomeric properties of rBet v 1-FV. Unlike nBet v 1 and rBet v 1-WT, rBet v 1-FV showed almost no IgE binding in immunoblots. The reduction of allergenicity was further proved by IgE-binding inhibition assays, basophil activation and histamine release. T cell reactivity was completely conserved, as demonstrated by proliferation of Bet v 1-specific T cell lines with multiple epitope specificities. rBet v 1-FV showed strong immunogenicity in mice. Conclusions: Due to its reduced IgE reactivity and decreased capacity to activate basophils, but retained T cell reactivity and strong immunogenicity, rBet v 1-FV proved to be a very promising candidate for specific immunotherapy in birch pollen-allergic subjects.Keywords
This publication has 41 references indexed in Scilit:
- Heat denaturation, a simple method to improve the immunotherapeutic potential of allergensEuropean Journal of Immunology, 2005
- Bet v 1142-156 is the dominant T-cell epitope of the major birch pollen allergen and important for cross-reactivity with Bet v 1–related food allergensJournal of Allergy and Clinical Immunology, 2005
- IL‐10 and TGF‐β cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapyEuropean Journal of Immunology, 2003
- Genetic Engineering of Recombinant Hypoallergenic Oligomers of the Major Birch Pollen Allergen, Bet v 1: Candidates for Specific ImmunotherapyInternational Archives of Allergy and Immunology, 1999
- Preserved epitope‐specific T cell activation by recombinant Bet v 1‐MBP fusion proteinsClinical & Experimental Allergy, 1998
- Dissection of immunoglobulin E and T lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1: potential use of hypoallergenic isoforms for immunotherapy.Journal of Experimental Medicine, 1996
- Characterization of Major Allergens of Parietaria officinalisInternational Archives of Allergy and Immunology, 1996
- Multiple T cell specificities for Bet v I, the major birch pollen allergen, within single individuals. Studies using specific T cell clones and overlapping peptidesEuropean Journal of Immunology, 1993
- Homology of the major birch-pollen allergen, Bet v I, with the major pollen allergens of alder, hazel, and hornbeam at the nucleic acid level as determined by cross-hybridizationJournal of Allergy and Clinical Immunology, 1991
- Computed circular dichroism spectra for the evaluation of protein conformationBiochemistry, 1969